Drug Detail

Information about Navitoclax + Sorafenib

Generic Name	Navitoclax + Sorafenib
IND
Brand Name (US)
Manufacturer
Drug Type
Delivery	Oral
Approval Status	Both are approved
Indications
Overall Strategy	KIT Protein Based + Oncogenic Signal Path Based
Strategy	Block KIT + Unblock cell death genes
Drug Category	BCL-2 inhibitor + KIT inhibitor

Links
Trials of this drug
	Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Trial results
	AACR Poster 8/15/2020 Abstract CT114: Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors